Acrivon Therapeutics, Inc. ACRV 深 沪

Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 21.82 percent increase over losses of $(0.55) per share from the same period last year.

08-13 04:23

Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study

Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose optimizati...

08-05 20:32

Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24

Presentations and Details Oral Podium Presentation Title: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug Discovery Presenter: Lei Shi, Ph.D., Director and Head, AP3 Pathway Discovery, Acrivon Therapeutics Session: Biotech Spotlight...

07-22 04:32

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics granted an employee 111,150 stock options under its 2023 Inducement Plan, vesting 25% after one year and monthly thereafter. The company's Generative Phosphoproteomics AP3 platform enables precision medicine discovery. Acrivon is advancing ACR-368 in a Phase 2 trial for endometrial cancer and developing ACR-2316, a WEE1/PKMYT1 inhibitor, with promising early data.

05-15 20:00

Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 3.92 percent increase over losses of $(0.51) per share

05-14 04:24

Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics

04-18 04:03

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

04-17 20:00

Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.57) by 13.58 percent. This is a 18.33 percent increase over losses of $(0.60) per share

03-19 19:23